Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10610953 | 0.86 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL1028048 | 0.86 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL21831286 | 0.86 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL31455691 | 0.85 | CA1 (0.52) | CA1CA2CA12CA9CA14 | |
| SCHEMBL84424 | 0.83 | CA1 (0.59) | CA1CA2CA12CA9CA14 | |
| SCHEMBL24073028 | 0.83 | ALDH1A1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL18309215 | 0.82 | CA1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL14488009 | 0.82 | CA1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL29013792 | 0.82 | CA1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28075695 | 0.82 | CA1 (0.40) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619922-A | Hydroxamic acid compound, and preparation method and application thereof | 郑州大学 | 2024-09-10 | — | — | CN | claimed |
| CN-104530078-A | Thieno [3, 2-d] pyrimidine derivative and preparation method and application thereof | UNIV SHANDONG | 2015-04-22 | — | — | CN | claimed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-3416633-B1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | UNIV ILLINOIS (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4537905-A2 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-3774789-B1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2025-03-05 | — | — | EP | disclosed |
| US-5234942-A | Treating allergic pulmonary disorders, asthma | ICI AMERICAS INC. (US) | 1993-08-10 | — | — | US | disclosed |
| WO-1993009185-A1 | LONG WAVELENGTH CHEMICALLY REACTIVE DIPYRROMETHENEBORON DIFLUORIDE DYES AND CONJUGATES | MOLECULAR PROBES, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
| CN-1055925-A | Pyridine derivate and preparation method thereof | ICI PLC (GB) | 1991-11-06 | — | — | CN | disclosed |
| CN-1050187-A | New quinoline compound and preparation method thereof | ICI PLC (GB) | 1991-03-27 | — | — | CN | disclosed |
| US-4997844-A | Compounds for the treatment of allergic or inflammatory diseases or shock conditions | ICI AMERICAS INC. (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0179619-B1 | HETEROCYCLIC AMIDES | ICI AMERICAS INC. (US) | 1990-09-05 | — | — | EP | disclosed |
| CN-1030755-A | INSECTICIDAL PYRAZOLINES | DU PONT (US) | 1989-02-01 | — | — | CN | disclosed |
| US-4616086-A | ANTICOAGULANTS | BOEHRINGER MANNHEIM GMBH (DE) | 1986-10-07 | — | — | US | disclosed |
| EP-0179619-A1 | Heterocyclic amides | ICI AMERICAS INC. (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | CA1 4427/4885CA2 4413/4885CA12 4283/4885 |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | CA1 1041/4885CA2 1873/4885CA12 3079/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | CA1 2045/4885CA2 2413/4885CA12 3603/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | CA1 4190/4885CA2 4078/4885CA12 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.